Stockscreener 앱 받기
67.34
2.15%
-1.4711
Ptc Therapeutics Inc 주식(PTCT)의 최신 뉴스
PTC Therapeutics, Inc. $PTCT Position Raised by Jefferies Financial Group Inc. - MarketBeat
Thrivent Financial for Lutherans Makes New $4.19 Million Investment in PTC Therapeutics, Inc. $PTCT - MarketBeat
United States Duchenne Muscular Dystrophy Therapeutics Market - openPR.com
BofA reiterates Buy on PTC Therapeutics stock citing Sephience launch momentum - Investing.com
PTC Therapeutics’ SWOT analysis: stock gains on rare disease drug launch - Investing.com India
PTC Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Q3 2025 PTC Therapeutics Inc Earnings Call Transcript - GuruFocus
PTC Therapeutics Q1 earnings call highlights - MSN
PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 2,812 Shares - MarketBeat
PTC Therapeutics (PTCT) CLO exercises options and sells 2,812 shares under 10b5-1 plan - Stock Titan
Oregon Public Employees Retirement Fund Invests $1.39 Million in PTC Therapeutics, Inc. $PTCT - MarketBeat
Analyst Forecasts For PTC Therapeutics, Inc. (NASDAQ:PTCT) Are Surging Higher - Sahm
Party Time: Brokers Just Made Major Increases To Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Earnings Forecasts - 富途牛牛
PTC Therapeutics CEO Matthew B. Klein sells $917,153 in stock By Investing.com - Investing.com South Africa
PTC Therapeutics CEO Matthew B. Klein sells $917,153 in stock - Investing.com
PTC Therapeutics (PTCT) CEO earns 12,500 RSUs, sells 12,572 shares for tax withholding - Stock Titan
TD Bank holds 3,025,945 PTC Therapeutics shares (NASDAQ: PTCT) — 3.7% - Stock Titan
Janus Henderson Group (NASDAQ: PTCT) holds 8.7% of PTC Therapeutics (7.19M shares) - Stock Titan
Form 144 notice — PTCT reports 2,812-share resale (PTCT) - Stock Titan
Matthew Klein sells PTCT shares; restricted stock vests (PTCT) - Stock Titan
PTCT (NASDAQ: PTCT) director sells shares; restricted stock vests - Stock Titan
PTC Therapeutics stock (US69366J2006): Rare disease focus amid biotech sector momentum - AD HOC NEWS
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Mark Elliott Boulding Sells 3,540 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
[Form 4] PTC THERAPEUTICS, INC. Insider Trading Activity - Stock Titan
Barclays Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $120 - Moomoo
Why PTC Therapeutics (PTCT) Is Up 12.5% After Beating Q1 Estimates And Lifting 2026 Guidance - Sahm
New Forecasts: Here's What Analysts Think The Future Holds For PTC Therapeutics, Inc. (NASDAQ:PTCT) - Yahoo Finance Australia
J.P. Morgan Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $89 - Moomoo
State of New Jersey Common Pension Fund D Sells 19,078 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics : Corporate Presentation – May 2026 - marketscreener.com
PTCT Soars As PTC Therapeutics Lifts 2026 Guidance And Beats Earnings - timothysykes.com
PTC Therapeutics stock sinks as pivotal data fails to calm sellers - MSN
PTC Therapeutics: Sephience Turns The Story From Regulatory Repair To Operating Leverage - Seeking Alpha
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2026 Earnings Call Transcript - Insider Monkey
PTC Therapeutics (PTCT) Gets a Buy from Raymond James - The Globe and Mail
PTC Therapeutics, Inc. $PTCT Shares Purchased by Comerica Bank - MarketBeat
PTC Therapeutics Raised to Buy From Hold by TD Cowen - Moomoo
PTCT Upgraded by TD Cowen -- Price Target Raised to $90 - GuruFocus
PTC Therapeutics (NASDAQ:PTCT) Releases Quarterly Earnings Results, Beats Estimates By $0.42 EPS - MarketBeat
PTC Therapeutics Lifts 2026 Outlook on Sephience Momentum - The Globe and Mail
PTC Therapeutics Q1 Earnings Call Highlights - MarketBeat
PTCT Maintains by RBC Capital -- Price Target Raised to $82.00 - GuruFocus
PTCT (NASDAQ: PTCT) affiliate plans to sell 3,540 shares; prior insider sales listed - Stock Titan
PTC Therapeutics Gains Fresh Nasdaq Today Attention - Kalkine Media
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $82.00 at Royal Bank Of Canada - MarketBeat
Update: PTC Therapeutics Shares Rise After Q1 Results Beat Consensus - Moomoo
RBC Capital Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Raises Target Price to $82 - Moomoo
PTCT Stock Jumps As Earnings Beat And Drug Data Fuel Bullish Momentum - StocksToTrade
PTCT Maintains Overweight Rating -- Price Target Raised to $95.0 - GuruFocus
PTC Therapeutics climbs after guidance hike (PTCT:NASDAQ) - Seeking Alpha
PTC Therapeutics (NASDAQ:PTCT) Given New $95.00 Price Target at Wells Fargo & Company - MarketBeat
2.25%
0.46%
자본화:
|
볼륨(24시간):